UCB and Biogen Announce Positive Efficacy Results for Dapirolizumab Pegol in Phase 3 PHOENYCS GO Study for Systemic Lupus Erythematosus
12/6 07:10
Dapirolizumab pegol demonstrated significant efficacy in reducing fatigue and disease activity in systemic lupus erythematosus patients during the PHOENYCS GO study....